Last reviewed · How we verify
Triamcinolone Acetonide Standard Dose
At a glance
| Generic name | Triamcinolone Acetonide Standard Dose |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Knee Injections for Obese Patients With Knee Arthritis (PHASE4)
- Topical Cryotherapy and Keloid/Hypertrophic Scars (PHASE3)
- Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus (PHASE2)
- The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis (PHASE4)
- Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain (NA)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata (NA)
- Safety and Effectiveness of Drop-free Small Incision Cataract Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone Acetonide Standard Dose CI brief — competitive landscape report
- Triamcinolone Acetonide Standard Dose updates RSS · CI watch RSS
- Mayo Clinic portfolio CI